A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors

被引：30

作者：

Di Cosimo, S.

Bendell, J. C.

Cervantes-Ruiperez, A.

Roda, D.

Prudkin, L.

Stein, M. N.

Leighton-Swayze, A.

Song, Y.

Ebbinghaus, S.

Baselga, J.

机构：

[1] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Univ Valencia, Hosp Clin, Valencia, Spain

[4] Univ Valencia, Hosp Clin Univ, Dept Surg, Dept Med Oncol,Colorectal Unit, Valencia, Spain

[5] Vall dHebron Univ Hosp, Barcelona, Spain

[6] Canc Inst New Jersey, New Brunswick, NJ USA

[7] Merck Res Labs, N Wales, PA USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.3008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3008

引用

页数：1